Although most systemic juvenile idiopathic arthritis patients don’t develop macrophage activation syndrome (MAS), the approximately 10% who do have this serious complication can experience widespread, massive inflammation, debilitating symptoms and even death. To improve understanding of MAS among physicians and advance efforts to develop effective therapies to treat it, a panel of 28 international pediatric…
The pathogenesis of and new classification criteria for MAS
Rheumatologists focus on similar clinical, laboratory findings to better
understand pathobiology of Ebola infection
Rheumatology’s premier event to be held in Boston from Nov. 14–19
Changing treatment paradigms in the biologic era
A review of diagnosis, treatment, and prognosis
Research helps hasten diagnosis and treatment of macrophage activation syndrome
Disease remission should be the goal for all rheumatologists treating childhood arthritis